| __timestamp | Alnylam Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 9757000 |
| Thursday, January 1, 2015 | 41097000 | 1253000 |
| Friday, January 1, 2016 | 47159000 | 5421000 |
| Sunday, January 1, 2017 | 89912000 | 154584000 |
| Monday, January 1, 2018 | 74908000 | 301034000 |
| Tuesday, January 1, 2019 | 219750000 | 380833000 |
| Wednesday, January 1, 2020 | 492853000 | 540099000 |
| Friday, January 1, 2021 | 844287000 | 701887000 |
| Saturday, January 1, 2022 | 1037418000 | 933013000 |
| Sunday, January 1, 2023 | 1828292000 | 1243336000 |
| Monday, January 1, 2024 | 2248243000 |
Unleashing insights
In the dynamic world of biotechnology, Alnylam Pharmaceuticals and Sarepta Therapeutics have emerged as key players, each carving out a unique path in the industry. Over the past decade, Alnylam has demonstrated a remarkable revenue growth trajectory, with a staggering increase of over 3,500% from 2014 to 2023. This growth is largely attributed to their innovative RNA interference therapies.
Sarepta, on the other hand, has also shown impressive growth, with revenues increasing by more than 12,600% in the same period, driven by their pioneering work in genetic medicine for rare diseases. By 2023, Alnylam's revenue reached approximately 1.8 billion, while Sarepta's stood at around 1.2 billion, showcasing their competitive edge in the biotech arena.
This comparison highlights the rapid advancements and potential of biotech companies in transforming healthcare and improving patient outcomes.
Revenue Insights: Pfizer Inc. and Sarepta Therapeutics, Inc. Performance Compared
Who Generates More Revenue? Takeda Pharmaceutical Company Limited or Alnylam Pharmaceuticals, Inc.
Comparing Revenue Performance: Takeda Pharmaceutical Company Limited or Sarepta Therapeutics, Inc.?
Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or Teva Pharmaceutical Industries Limited?
Annual Revenue Comparison: Alnylam Pharmaceuticals, Inc. vs Catalent, Inc.
Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.: Annual Revenue Growth Compared
Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or MiMedx Group, Inc.?
Revenue Insights: Genmab A/S and Sarepta Therapeutics, Inc. Performance Compared
Revenue Showdown: Sarepta Therapeutics, Inc. vs Perrigo Company plc
Annual Revenue Comparison: Sarepta Therapeutics, Inc. vs Vericel Corporation
Who Generates More Revenue? Sarepta Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.